Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah C Wise

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Cell|June 12, 2019
Precision Oncology: Three Small Steps ForwardHannah C Wise, David B Solit
Scientific Reports|December 13, 2019
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer ModelsHannah C Wise, Gopakumar V Iyer, Kathleen Moore, et al.
Advances in Therapy|March 2, 2025
Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin LymphomaMadeline Richey, Christina Fullerton, Qianyi Zhang, et al.
Molecular Cancer Research : MCR|December 11, 2020
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin SignalingSizhi Paul Gao, Amber J Kiliti, Kai Zhang, et al.
Cancer Research|July 10, 2020
Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in CancerAphrothiti J Hanrahan, Brooke E Sylvester, Matthew T Chang, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Cell|June 12, 2019
Precision Oncology: Three Small Steps ForwardHannah C Wise, David B Solit
Scientific Reports|December 13, 2019
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer ModelsHannah C Wise, Gopakumar V Iyer, Kathleen Moore, et al.
Advances in Therapy|March 2, 2025
Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin LymphomaMadeline Richey, Christina Fullerton, Qianyi Zhang, et al.
Molecular Cancer Research : MCR|December 11, 2020
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin SignalingSizhi Paul Gao, Amber J Kiliti, Kai Zhang, et al.
Cancer Research|July 10, 2020
Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in CancerAphrothiti J Hanrahan, Brooke E Sylvester, Matthew T Chang, et al.
Pageof 1